Spinouts

 

Explore our portfolio below. We typically launch 3 new companies every year, with plans to step this up, so follow us on LinkedIn to stay up to date with our work.

Queen Mary spinout companies raised £5m in investment in 2022/23, and have raised over £100m since 2018/19. If you’re an investor, it’s best to contact the company directly to learn what form of investment they’re looking for. 

We work with around 150 researchers each year to assess the viability of their inventions. We’ve worked with 650 individual researchers since 2018/19. If you’re a researcher at Queen Mary, get in touch to discuss how we can help you develop your idea into a business.

Our spinouts are special because they are the fruits of significant scientific discoveries. 92% of our research is world leading or internationally excellent (REF 2021) and we’re ranked 14th in the world for the quality of our research (THE World University Ranking 2024).

elcella

elcella

A unique nutrient-based appetite suppressant which releases your body’s natural ability to control your eating – based on a decade of scientific research.
Syntex

Syntex

A new material for synthetic heart valves which will enable patients to live lives indistinguishable from having a healthy heart.
Dragonfly AI

Dragonfly AI

A biologically inspired algorithm to test creative content by predicting human attention.
Arbitrator Intelligence

Arbitrator Intelligence

Transparency, accountability, and diversity in arbitrator selection.
Nilocas

Nilocas

Nilocas Ltd is developing a medical device to revolutionise the detection of Coronary Artery Disease.
Bela

Bela

The finest tools for ambitious creators who are working with sensors and sound.
LANDR

LANDR

AI-powered music mastering, distribution, plugins, collaboration, promotion and sample packs.
Ultima Forma

Ultima Forma

Extending the limits of product performance with advanced forming technology.
VacV Biotherapeutics

VacV Biotherapeutics

An immunotherapy company developing viral-based therapies for cancer.
Kinomica

Kinomica

A diagnostic platform to help clinicians prescribe the right drug, for the right patient, at the right time.
BioMin

BioMin

BioMin glass is a dental additive for complete oral care and protection.
Warblr

Warblr

An iPhone and Android app that automatically recognises British birds by their song.
Keratify

Keratify

A more effective way to maintain skin in culture.
Tabletop R&D

Tabletop R&D

AI-powered playtesting for designing better board games faster.
SequenceServer

SequenceServer

Intuitive comparison and visualisation of DNA and protein sequences.
AeroSolar

AeroSolar

Manufacturing a new kind of solar cell made from perovskite.
Pryfiber

Pryfiber

An AI algorithm for real-time image calibration during surgical or imaging procedures.
Nemisindo

Nemisindo

Generating unique sound effects in real time using AI.
RoEx

RoEx

Using AI to transform how musicians of all skill levels produce and record new music.
DAACI AI

DAACI AI

DAACI’s generative tech encodes composers’ musical ideas, allowing their AI to dynamically compose in real time without relying on pre-recorded samples.
Chatterbox Labs

Chatterbox Labs

Addressing the unintended consequences of AI.
hVIVO

hVIVO

The world leader in human challenge studies to test infectious and respiratory products.
The Government’s spinout review

We are pleased to be incorporating the good practice recommendations from the Government spinout review in its policy and practices. In particular we welcome the work done by TenU and major investors in developing the USIT guides as a landing zone and foundation for good practices and we will be using them in our commercialisation activities.

At Queen Mary Innovation we work on behalf of the University to maximise the impact of Queen Mary Research using commercial tools and implements the University Intellectual Property policy. The primary goal is to ensure economic and social impact, and any returns are shared with innovative creators and venture founders, reinvested in new ventures, or in the University’s charitable mission.

Following the Government review the University is currently reviewing its Intellectual Property Policy, which covers more than just the creation of spinouts and requires wider consultation. Nevertheless, recognising the importance of increasing the speed and scale of spinouts as quickly as possible, the University has approved a new Commercialisation and Benefit Sharing Policy which will operate from the 5th July 2024 and will be incorporated into the full Intellectual Property policy once the review is complete.

We will immediately implement the policy and we’ll continue to review its procedures to identify areas where decision making can sensibly be streamlined to ensure speedier conclusion of discussions with investors and stakeholders.